NASD · Healthcare · Diagnostics & Research · USA
Guardant Health Inc is a large cap company (market value between $10 billion and $200 billion) in the Diagnostics & Research industry.
Guardant Health is a precision oncology company providing blood and tissue tests for cancer detection and monitoring across disease stages. Its products include Guardant360 tests for therapy selection in advanced cancer, Guardant Reveal for detecting residual disease in early-stage cancer, and Shield for colorectal cancer screening. The company collaborates with biopharmaceutical firms on clinical studies.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Guardant Health Inc stock.
Overvalued: intrinsic value $15.64 per share, market price $157.88, margin of safety -909.5% (as of 2026-10-19).
A 2.7x revenue multiple, discounted for its losses, values the shares at $15.64; the price of $157.88 is 910% above that value.
Leak Score: 39/100 on 8 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
22 more in this industry show a wider margin of safety.
GH is overvalued (as of the 2026-10-19 close). A 2.7x revenue multiple, discounted for its losses, values the shares at $15.64; the price of $157.88 is 910% above that value.
$15.64 per share (as of the 2026-10-19 close), against a market price of $157.88. That is a margin of safety of -909.5%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
39 out of 100, which we rate "On Watch", on 8 of 12 value investing signals.